List of Clinical Trials

Updated September 13, 2016

In addition to the therapies approved by Health Canada, patients may be able to access several other therapies through clinical trials. By participating in a clinical trial, you will be helping researchers answer important questions that will further the development of new treatments and new treatment guidelines. Also, clinical trials often give you another option in your treatment plan.

Kidney Cancer Canada makes every effort to be aware of major clinical trials for renal cell carcinoma across Canada. As a patient with renal cell carcinoma, you may be eligible to access a therapy through a clinical trial depending upon:

  • Your sub-type of kidney cancer (e.g., clear cell renal cell carcinoma or other)
  • Your stage of disease (e.g., whether or not you have metastasis)
  • Whether you have had one or more prior therapies

For ease of reference, we have organized major clinical trials into groupings below according to where you are on the treatment journey. For example, you’ll find trials for patients who have just recently been diagnosed and are pre-surgery or clinical trials for those for patients who have already had several systemic therapies.

 

Pre-Surgery (Neoadjuvant) Trials

The purpose of Neoadjuvant trials is to determine whether treatments that are proven to be effective with metastatic kidney cancer can also be used effectively before surgery to reduce the size of tumours.

 

Trial ID: NCT02212730
A Study Evaluating the Effect of Neoadjuvant Pembrolizumab (MK-3475, Keytruda®) in  Renal Cell Cancer Patients Undergoing Surgical Resection (MK-3475-031, KEYNOTE 031). Pembrolizumab is an immuno-oncology drug. It will be given before surgery in newly diagnosed patients with kidney cancer. Find out more about this study.
Princess Margaret Centre Toronto Recruiting
Merck Canada Kirkland, Québec Recruiting

Trial ID: NCT01099423
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME)
This trial is no longer recruiting patients   Closed

Primary Treatment Trials

 

Trial ID: NCT01529658 
Renal Hypothermia During Partial Nephrectomy Study. This study will see if renal hypothermia (cooling) during open partial nephrectomy surgery can result in better kidney function after surgery compared to the warming technique. Find out more about this study.
St. Joseph's Health Centre Hamilton Recruiting 
London Health Sciences Centre London Recruiting
The Ottawa Hospital Ottawa Recruiting 
Princess Margaret Cancer Centre/UHN Toronto Recruiting
Centre hospitalier universitaire de Québec Québec Recruiting
QEII Health Sciences Centre Halifax Recruiting

Trial ID: NCT01720706 
A Study of Thermal Ablation for Treating Larger Liver and Kidney Tumours. This study is looking at the safety and effectiveness using a new radiofrequency thermal therapy compared to the standard radiofrequency ablation (RFA) treatment to treat large tumours in the kidney or liver. Find out more about this study.
University of Health Network (UHN) Toronto Recruiting 

Trial ID: NCT01305330
The Natural History of Small Renal Masses (Role of Active Surveillance and Identification of Prognostic Factors for Progression in Early Stage RCC). Small renal masses are less than 4 cm. Researchers will use imaging studies and tissue tests to try to find out which kidney masses grow and behave aggressively. Find out more about this study
Princess Margaret Hospital/University Health Network Toronto Recruiting

 Trial ID: NCT01582672, AGS-003-007 (Argos Therapeutics, Inc.)
Trial of Autologous Dendritic Cell Immunotherapy (AG3-003), plus Standard Treatment in People with Advanced Renal Cell Carcinoma Who Have Not Undergone a Nephrectomy (ADAPT study).
This trial is no longer recruiting patients   Closed

Trial ID: NCT01413607
A Study Using Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy. This study is looking at using a different type of suture (stitch) during partial nephrectomy surgery to see if there are fewer problems after surgery compared with traditional sutures. Find out more about this study.
QEII Health Sciences Centre Halifax Not yet recruiting

Trial ID: NCT02701712

Receiving Radiation Therapy at a Resonance Guided Radiation Therapy (MRgRT) Research Facility Study. This study is looking at how well MRgRT performs for evaluating solid and metastatic tumours in adults at the Princess Margaret Cancer Centre and the impact on the workflow of the clinical team in this facility. Find out more about this study.

Princess Margaret Hospital/UHN Toronto Recruiting

Post-Surgery with no Metastases (Adjuvant) Trials

The purpose of Adjuvant trials is to determine whether treatments that are proven to be effective with metastatic kidney cancer can also be used effectively to slow or prevent recurrence after surgical treatment.

 

There are no adjuvant trials that are open and recruiting patients in Canada at this time.

First-Line Treatment (means no prior systemic therapy)

In addition to proven first-line treatments for kidney cancer, patients who have not had any prior systemic therapy for their metastatic disease have several treatment options.

 

Trial ID: NCT02019576
Stereotactic Radiotherapy (SRT) for Metastatic Kidney Cancer Being Treated With Sunitinib (Sutent®). SRT is a newer type of focused radiation therapy that precisely and accurately delivers high dose radiation to a tumour, while sparing much of the nearby normal organs. This study will measure how well SRT can destroy kidney cancer tumours in patients taking the targeted therapy sunitinib. 
Find out more about this study.
BC Cancer Agency Vancouver Not yet recruiting
Tom Baker Cancer Centre Calgary Not yet recruiting
Cross Cancer Institute Edmonton Not yet recruiting
CancerCare Manitoba Winnipeg Recruiting
Hamilton Health Sciences Centre Hamilton  Not yet recruiting
London Health Sciences Centre London Not yet recruiting
Ottawa Hospital Cancer Centre Ottawa Not yet recruiting
Sunnybrook Health Sciences Centre Toronto Recruiting
Princess Margaret Cancer Centre Toronto Not yet recruiting
Jewish General Hospital Montréal Recruiting
CHUM, Hôpital Notre-Dame Montréal Recruiting
McGill University Health Centre Montréal Not yet recruiting
QEII Health Sciences Centre Halifax Not yet recruiting

Trial ID: NCT02420821 
A Study of Atezolizumab (MPDL3280A,Tecentriq®) plus Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Patients With Untreated Advanced Renal Cell Cancer [IMmotion151]. Atezolizumab is an immuno-oncology therapy, a PD-L1 checkpoint inhibitor. Bevacizumab and sunitinib are targeted therapies. Find out more about this study.
London Regional Cancer Centre London Not yet recruiting
Sunnybrook Health Sciences Centre Toronto Not yet recruiting
Princess Margaret Cancer Centre Toronto Not yet recruiting
Durham Regional Cancer Centre Oshawa Recruiting
Jewish General Hospital Montréal Recruiting
Hôtel Dieu de Québec Québec Recruiting
QEII Health Sciences Centre Halifax Recruiting

Trial ID: NCT02231749
Nivolumab (Opdivo®) Combined with Ipilimumab (Yervoy®) versus Sunitinib (Sutent®) in Previously Untreated, Advanced or Metastatic Renal Cell Cancer (CheckMate 214). Nivolumab and ipilimumab are immuno-oncology therapies and sunitinib is a targeted therapy drug.
This trial is no longer recruiting patients   Closed

Trial ID: NCT02684006
A Study of a Drug called Avelumab (MSB0010718C) given along with the Drug, Axitinib (Inlyta®) compared to using Sunitinib (Sutent®) by itself, as First-line Treatment in Patients with Advanced (or Metastatic) Renal Cell Cancer (JAVELIN Renal 101). Avelumab is an experimental immune-oncology therapy drug. Axitinib and sunitinib are targeted therapy drugs.
Find out more about this study.
BC Cancer Agency Vancouver Not yet recruiting
BC Cancer Agency - Sindi Ahluwalia Hawkins Centre for the Southern Interior Kelowna Not yet recruiting
Cross Cancer Institute Edmonton Recruiting
CIUSSS de l'Estrie - Centre hospitalier universitaire de Sherbrooke Sherbrooke, Québec Recruiting

Trial ID: NCT02853331
A Study Evaluating the Safety and Effect of a Drug called Pembrolizumab (MK-3475, Keytruda®) Given With the Drug Axitinib (Inlyta®), Compared to the Drug Sunitinib (Sutent) as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Cancer (MK-3475-426, KEYNOTE 426 study). Pembrolizumab is an immuno-oncology therapy drug. Axitinib and sunitinib are targeted therapy drugs.
Find out more about this study.
Merck Canada Kirkland, Québec Not yet recruiting

Second Line Treatment (only one prior systemic therapy)

 

Trial ID: NCT01482949
A Rollover Study for Patients Previously Treated with AGS-003. This study is testing the activity and safety of an immuno-oncology treatment called AGS-003 in patients with renal cell cancer who have had a prolonged response or stable disease and continue to benefit from treatment with AGS-003 and were taking part in the studies AGS-003-004 or AGS-003-006. Find out more about this study.
Jewish General Hospital Montréal Status unknown. May no longer be recruiting patients

Trial ID: NCT02298959
A Study of Pembrolizumab (MK-3475, Keytruda®) and Ziv-aflibercept (Zaltrap®) in Treating Patients With Advanced Solid Tumours, including Metastatic or Recurrent Renal Cell Cancer. Pembrolizumab in a new immuno-oncology drug and Ziv-aflibercept is a targeted vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). Patients can have had at least 1 prior targeted therapy with a VEGF TKI. Find out more about this study.
BC Cancer Agency Vancouver Recruiting
Princess Margaret Hospital/UHN Toronto Recruiting

Trial ID: NCT02304393
A Study of a Drug called RO7009789 (a CD40 Agonist) in Combination with a drug called Atezolizumab (MPDL3280A, Tecentriq®, a PD-L1 inhibitor) in Patients with Locally Advanced or Metastatic Solid Tumours. RO7009789 is an experimental immuno-oncology drug. Atezolizumab is also an immuno-oncology drug but it works in a different way. Tumours must be able to be biopsied. Patients cannot have had prior immuno-oncology drug treatment with an anti-CTLA-4, anti-PD-1, or anti-PD-L1 drug, or drugs that target CD40. Find out more about this study.
Jewish General Hospital Montréal Recruiting
Princess Margaret Hospital Toronto Not yet recruiting

Trial ID: NCT02665416
A Study to assess the safety and effectiveness of a drug called RO7009789 (a CD40 Agonist) in Combination with Vanucizumab (RG 7221, also known as RO 5520985) in Patients with Advanced or Metastatic Solid Tumours (including kidney cancer). RO7009789 is an experimental immuno-oncology drug. Vanucizumab is a targeted therapy VEGF inhibitor drug. Note: Patients cannot have had prior treatment with a VEGF inhibitor within 12 months of going on this study. This study is for patients for whom no standard therapy is available. Find out more about this study.
Princess Margaret Hospital Toronto Recruiting

Trial ID: NCT02598960
A Study of a Drug called BMS-986156 Given Alone or Along With Nivolumab (Opdivo®) in Patients With Advanced Solid Tumours. Patients can have had previous treatment for advanced or metastatic solid tumours or solid tumours that are no longer responding to treatment (are refractory to treatment). BMS-986156 is an experimental drug. Nivolumab is a new immuno-oncology drug. Find out more about this study.
BC Cancer Agency  Vancouver Not yet recruiting
Cross Cancer Agency Edmonton Not yet recruiting
Princess Margaret Hospital Toronto Recruiting

Trial ID: NCT02761057
A Study of Cabozantinib (Cometriq®, BMS-907351), or Crizotinib (Xalkori®), or Volitinib (AZD6094, Savolitinib), or Sunitinib (Sutent®) in Treating Patients With Locally Advanced (spread from where it started in the kidney to nearby tissue or lymph nodes) or Metastatic Papillary Kidney Cancer (also called the PAPMET study). Cabozantinib, crizotinib and volitinib are drugs called MET inhibitors. Sunitinib is a targeted tyrosine kinase inhibitor (TKI) therapy. This study is looking to see which of these drugs can stop the growth of tumour cells by blocking some of the enzymes needed for cell growth. Patients may have had prior surgery, 1 prior systemic therapy or prior radiation therapy for advanced or metastatic kidney cancer. Find out more about this study.
We do not have a list of participating Canadian centres to date.   Recruiting

Trial ID: NCT02599779
A Proof of Principle Study of the Activity of Pembrolizumab (MK-3475, Keytruda®) Given in Combination with Stereotactic Body Radiation Therapy (SBRT) in Patients with Metastatic Kidney Cancer. Patients who are not responding to targeted therapy with a tyrosine kinase inhibitor (TKI), they are TKI refractory, can take part in this study. Pembrolizumab is an immuno-oncology drug. SBRT is a very precise way of giving radiation therapy to tumours. Find out more about this study.
BC Cancer Agency  Vancouver Not yet recruiting
Tom Baker Cancer Centre Calgary Not yet recruiting
Princess Margaret Hospital Toronto Not yet recruiting
Sunnybrook Health Sciences Centre Toronto Not yet recruiting
The Ottawa Hospital Ottawa Not yet recruiting

Trial ID: NCT02426125
A Study of a Drug called Ramucirumab (LY3009806) Given With the Drug Docetaxel (Taxotere®), Compared to Docetaxel By Itself in Patients With Urothelial Carcinoma Whose Cancer has Progressed On or After Platinum-containing Chemotherapy (RANGE study). Ramucirumab is a new targeted therapy drug. Docetaxel is a chemotherapy drug that is used to treat certain types of cancer. This study is for patients with locally advanced, unoperable (unresectable) or metastatic urothelial (transitional cell) cancer of the bladder, urethra, ureter, or renal pelvis. Find out more about this study
Eli Lilly and Company – Contact for participating locations. Vancouver
Edmonton
Toronto
Montréal
Recruiting

Trial ID: NCT02285816
A Study to Find the Best Dose of a New Therapy called MG1 Maraba/MAGE-A3 virus, Given by Itself or With an Adenovirus Vaccine, in Patients With Incurable MAGE-A3-Expressing Solid Tumours (I214). This study is for patients with inoperable locally advanced or metastatic solid tumours that positively express MAGE-A3 and for whom there is no known standard therapy. Patients can have had at least 1 prior first-line treatment for advanced or metastatic disease, but there is really no limit to the number of prior treatment regimens to take part. Find out more about this study
BC Cancer Agency  Vancouver Recruiting
Hamilton Health Sciences Centre Hamilton Recruiting
Princess Margaret Hospital/UHN Toronto Recruiting
The Ottawa Hospital Ottawa Recruiting

Trial ID: NCT02033993
A Trial Comparing Nab-Paclitaxel to Paclitaxel (Taxol®) in Patients With Advanced Urothelial Cancer, whose Cancer is Progressing On or After having a Platinum-containing Chemotherapy. Nab-Paclitaxel is a combination of the chemotherapy drug Paclitaxel and a human protein. Paclitaxel is a chemotherapy drug used to treat certain types of cancer. Patients with transitional cell cancer (TCC) of the urinary tract (bladder, urethra, ureter, or renal pelvis) and metastatic or locally advanced inoperable disease can take part in this study. Patients must have received only 1 prior chemotherapy, which included a platinum drug for metastatic or recurrent disease. Find out more about this study.
BC Cancer Agency  Vancouver Recruiting
Cross Cancer Agency Edmonton Recruiting
Tom Baker Cancer Centre Calgary Recruiting
Saskatoon Cancer Centre Saskatoon Recruiting
Allan Blair Cancer Centre Regina Recruiting
Cancer Centre Of Southeastern Ontario  Kingston Recruiting 
Durham Regional Cancer Centre Oshawa Recruiting 
Hamilton Health Sciences Centre Hamilton Recruiting 
London Health Sciences Centre London Recruiting 
Princess Margaret Hospital/UHN Toronto  Recruiting 
The Ottawa Hospital Ottawa Recruiting
Southlake Regional Health Centre Newmarket Recruiting 
CHUS Hôpital Fleurimont Sherbrooke  Recruiting 
CISSS de la Montérégie-Centre - Hôpital Charles LeMoyne Greenfield Park Recruiting 
CSSS de Trois-Rivières - CHAUR Trois-Rivières Recruiting 
CHUM Hôpital Notre-Dame Montréal  Recruiting 
Jewish General Hospital Montréal  Recruiting 
QEII Health Sciences Centre Halifax  Recruiting

Trial ID: NCT02091999, ASG-22CE-13-2
A Study of Increasing Doses of ASG-22CE Given By Itself in Patients With Metastatic Urothelial Cancer and Other Malignant Solid Tumours That Express Nectin-4. This study will be looking at the safety and anti-cancer activity of an experimental drug called ASG-22CE in patients with recurrent metastatic cancer of the urinary tract (bladder, urethra, ureter, or renal pelvis) and other malignant solid tumours. ASG-22CE is a drug that targets nectin-4, a tumour antigen that is overexpressed in certain cancers. Patients can have had 1 prior systemic therapy and their cancer continues to grow despite treatment. Find out more about this study.
BC Cancer Agency  Vancouver Recruiting
Cross Cancer Agency Edmonton Recruiting
Princess Margaret Cancer Centre Toronto Recruiting

Third Line Treatment (up to two prior systemic therapies)



Trial ID: NCT02460224
A Study of the Safety, Effectiveness and Dosing of a Drug called LAG525, used by Itself and in Combination With another Drug called PDR001, in Patients With Advanced Cancer. LAG525 and PDR001 are experimental immuno-oncology drugs. Patients with advanced or metastatic solid tumours (including kidney cancer) with at least 1 measurable lesion or mass and whose cancer has continued to grow despite prior treatment may take part in this study. Find out more about this study.
Novartis Investigative Site Toronto Recruiting

Trial ID: NCT02754141
A Study to Assess the Safety and Effectiveness of a Drug called BMS-986179 when given along with Nivolumab (Opdivo®) in Patients with Advanced Cancer. BMS-986179 is an experimental drug. Nivolumab is a new immuno-oncology drug. This study is for patients with solid advanced tumours (including kidney cancer). Find out more about this study.
Princess Margaret Hospital Toronto Not yet recruiting
Ottawa Hospital Ottawa Not yet recruiting

Trial ID: NCT02644369
A Study of the Effects of a Drug called Pembrolizumab (MK-3475, Keytruda®) in Patients With Advanced or Metastatic Solid Tumours (INSPIRE-001). Pembrolizumab is a PD-L1 inhibitor immuno-oncology drug. Patients can have had prior therapy and there is no standard treatment for their cancer. Find out more about this study.
Princess Margaret Hospital Toronto Recruiting

Trial ID: NCT02639182
A Study of a Drug called AGS-16C3F compared to Axitinib (Inlyta®) in Patients with Metastatic Renal Cell Cancer. AGS-16C3F is an experimental immuno-oncology drug. Axitinib is a targeted therapy drug. This study is for patients whose cancer continues to grow and they have had at least 2 prior systemic therapies (for clear cell kidney cancer), or 1 prior systemic therapy (for non-clear cell kidney cancer), one of which can have been a targeted therapy with a VEGF inhibitor. Find out more about this study.
BC Cancer Agency Vancouver Recruiting
BCCA Centre for the Southern Interior Kelowna Recruiting
Cross Cancer Institute Edmonton Recruiting
Tom Baker Cancer Institute Calgary Recruiting
Juravinski Cancer Centre/Hamilton Health Sciences Hamilton Recruiting

Trial ID: NCT02655822
A Study to Evaluate the Safety and Anti-cancer Activity of a Drug called CPI-444 Given by Itself and also in Combination With Another Drug, called Atezolizumab (MPDL3280A, Tecentriq®), in Patients with Advanced Cancers, including Renal Cell Cancer. CPI-444 is an experimental immuno-oncology drug. Atezolizumab is also an immuno-oncology drug. Patients may have had 1, but not more than 5 prior systemic therapies for advanced, recurrent or progressing kidney cancer. Find out more about this study.
Cross Cancer Institute Edmonton Recruiting
Juravinski Cancer Centre Hamilton Recruiting

Trial ID: NCT02608268
A Study of the Safety and Effectiveness of a Drug called MBG453, used by Itself and in Combination With another Drug called PDR001, in Patients With Advanced Cancer (including Renal Cancer). MBG453 and PDR001 are experimental immuno-oncology drugs. Patients with advanced or metastatic solid tumours whose cancer has continued to grow despite standard treatment, or who can no longer tolerate standard treatment, or for whom no standard therapy exists can take part in this study. Find out more about this study.
Novartis Investigative Site Toronto Recruiting

Trial ID: NCT01638533
A Study of Side Effects and Best Dose of Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumours With Liver Dysfunction. Patients with recurrent renal cell cancer and moderate or severe liver dysfunction may take part in this study. Romidepsin (Istodax®) is a chemotherapy drug used to treat certain types of lymphoma. Find out more about this study.
Princess Margaret Hospital Toronto Recruiting

Other Clinical Trials (not included under categories above)

Trial ID: NCT00323076
An Imaging Study (PET Scan Imaging) in Patients With Cancer of the Head and Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours using a PET Tracer called 18F-FAZA. Find out more about this study.
Cross Cancer Institute Edmonton Recruiting

Trial ID: NCT01141816
Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation (RFA) of Kidney Lesions. This study will be looking at whether a different technique, called contrast-enhanced ultrasound, can be used to follow kidney cancer patients who have had RFA treatment instead of using CT scans (or MRIs). Find out more about this study.
Hamilton Health Sciences Hamilton Not yet recruiting

Trial ID: NCT01353521
Contrast-enhanced Ultrasound to Evaluate Complex Renal Cysts. This study will be looking at whether a contrast-enhanced ultrasound can accurately image complex renal cysts compared to CT scans (or MRIs). Find out more about this study.
St. Joseph’s Healthcare Hamilton Recruiting

Trial ID: NCT01065805
A Study to See How Safe and Effective Imaging with the Radiotracer 18F-FLT and PET Scan is in Patients With Known or Suspected Solid Tumours (including Renal Cell Cancer) or Lymphoma. Find out more about this study.
Cross Cancer Institute Edmonton Recruiting

Trial ID: NCT02428335
A Study of Muscle Energy Metabolism in Patients With Renal Cell Cancer Treated With Sunitinib (Sutent®). This study will use a special type of scan (technetium-99m sestamibi) to study fatigue, a very common side effect of the targeted therapy sunitinib, in relation to exercise. Find out more about this study
Cross Cancer Institute Edmonton Not yet recruiting

RADIATION THERAPY TRIALS


Trial ID: NCT01446744
Stereotactic Ablative Radiation Therapy for Comprehensive Treatment of Oligometastatic Tumours (SABR-COMET study). Stereotactic Ablative Radiotherapy (SABR) is a new radiation treatment that allows radiation treatment to be focused more precisely and delivered more accurately than older treatments. This study will compare SABR with current approaches of chemotherapy and conventional radiation therapy to assess the effect on patient survival and quality of life. When there are a limited number of metastatic tumours, these may be referred to as oligometastases. Find out more about this study
BC Cancer Agency Vancouver Recruiting
London Health Sciences Centre London Recruiting
Juravinski Cancer Centre/Hamilton Health Sciences Hamilton Recruiting
The Ottawa Hospital Cancer Centre Ottawa Recruiting
Northeastern Ontario Regional Cancer Centre Sudbury Recruiting
McGill University Health Centre Montréal Recruiting
Atlantic Clinical Cancer Research,
QEII Health Sciences Centre
Halifax Recruiting

Trial ID: NCT01761929

A Five Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases in Solid Tumours (including Kidney Tumours). SBRT delivers higher doses of radiation therapy to the tumour, while limiting the dose of radiation to the normal tissues. This study is for patients whose cancer is confined to a limited number of areas. Find out more about this study.

Princess Margaret Cancer Centre/UHN Toronto Recruiting

Trial ID: NCT02264548
Integrating Hypofractionated Renal Ablative Radiation Therapy in Patients with Metastatic Renal Cell Cancer. With hypofractionated radiation therapy, the radiation dose is divided into larger doses, but given over a shorter period of timeFind out more about this study.
London Health Sciences Centre London Recruiting


PROGNOSTIC OR PREDITIVE MARKERS STUDIES

Trial ID: NCT02499458
Prospective Validation of Circulating Tumour Cells and Circulating Endothelial Cells as Biomarkers in Clear Cell Renal Cancer. Circulating tumor cells (CTCs) have prognostic value in several tumour types and may help researchers better understand and address treatment resistance. This study will look at CTCs in metastatic clear cell renal cancer that may serve as prognostic or predictive biomarkers to improve treatment. Find out more about this study
London Health Sciences Centre London Recruiting


SUPPORTIVE CARE TRIALS

Trial ID: NCT02428335
A Study of Muscle Energy Metabolism in Patients With Renal Cell Cancer Treated With Sunitinib (Sutent®). This study will use a special type of scan (technetium-99m sestamibi) to study fatigue, a very common side effect of the targeted therapy sunitinib, in relation to exercise. Find out more about this study
Cross Cancer Institute Edmonton Not yet recruiting

Help us keep the list current

Please note: This list is not intended to be exhaustive. Some clinical trials may not be listed here. To find more information and locations where the clinical trials are available within Canada go to:

For clinical trials in the United States and other global locations (including Canada), please see:

If you are aware of a trial for renal cell carcinoma that is not listed here, please let us know by e-mail so that we can share the information with others.

I found a clinical trial : What next?

If you find a clinical trial that may be of interest to you, take the information to your physician to discuss it in more detail. Please REGISTER with Kidney Cancer Canada and join the Discussion Forum to reach out to other patients participating in a clinical trial or to ask a specific question.

SHOULD I JOIN A CLINICAL TRIAL?